Travere Therapeutics ($TVTX): FSGS Patent Allowance Points to FILSPARI Coverage Into 2037

01 Bull, Base and Bear Cases

Bull case

FILSPARI continues to compound in IgAN, the FSGS launch adds a clearly measurable second growth layer, payer access remains manageable and revenue growth creates consistent operating leverage. HARMONY stays on schedule, civorebrutinib receives a disciplined multi-indication development plan and international milestones add non-dilutive cash.

Base case

FILSPARI remains a strong franchise, but indication-level PSF disclosure stays limited and the FSGS curve develops gradually. Commercial growth is partly offset by royalties, SG&A, pipeline spending and debt costs. Travere remains financially secure but trades mainly on quarterly execution until HARMONY becomes closer.

Bear case

FSGS adoption is slower than expected, IgAN competition limits growth, payer restrictions increase and the company spends aggressively on civorebrutinib before the asset is sufficiently de-risked. A HARMONY delay or manufacturing problem would then increase reliance on FILSPARI while convertible dilution and debt remain in the capital structure.

What Would Falsify This Reading

The assessment is that FILSPARI commercial growth could fund a broader franchise, subject to costs, capital structure and clinical execution. The observations below would test that assessment in either direction. They are not predictions.

• FILSPARI growth stops compounding. United States FILSPARI sales were $141.1 million in the second quarter of 2026, up 96% year on year, with total net product sales of $161.4 million in the quarter and $285.8 million over six months. Persistent demand weakness, distinguished from channel inventory or revenue timing, would challenge the growth thesis. One flat quarter alone would not establish that change.
• The allowed FSGS patent does not issue, or is narrowed. A notice of allowance is the patent office saying it intends to grant a patent on the claims as they stand. It is not the granted patent, and the coverage into 2037 that this page describes depends on issuance and on the claims surviving any later challenge.
• Gross-to-net or payer mix deteriorates. Reported net sales depend on estimates for discounts, rebates, chargebacks and patient assistance. A shift in the payer mix, or a revision to those estimates, can change reported revenue without any change in the number of patients treated.
• Funding requirements change. Unexpected cash consumption, costly refinancing or larger share issuance would weaken the capital-allocation case. Sustained cash generation after development investment would strengthen it. No single revenue figure settles that balance.
• Pipeline evidence changes. HARMONY has a company-guided H2 2027 data window, without an exact release date. Success could support diversification but would still require regulatory and commercial execution; failure would increase dependence on FILSPARI. Civorebrutinib remains investigational.

These are observable developments that could change the assessment, positively or negatively, rather than predictions.

02 Q2 2026 Financial Results

FILSPARI quarterly sales comparison

FILSPARI nearly doubled year over year. The growth reflects continued IgAN adoption plus the beginning of the FSGS commercial contribution after the April 13 approval.

03 Other Program Updates

SPARX

Enrollment is complete in the study evaluating FILSPARI in patients with recurrent IgAN or FSGS after kidney transplant. Results are expected in 2027. The study could support broader physician use and future evidence generation, but it is not currently a registration catalyst.

SPARLIGHT

The August 4 update targets H2 2026 initiation of SPARLIGHT, a Phase 4 open-label, single-arm, multicenter study in adults and children of African ancestry with FSGS at high risk of progression. This is a company-guided start window, not confirmation of enrollment or a results date. Primary source

Japan

Partner Chugai submitted a New Drug Application for sparsentan in Japan in June 2026. Travere remains eligible for milestones and tiered royalties, creating international optionality without carrying the full commercial cost.

04 Why TVTX Matters After the FSGS Approval

The April 13, 2026 FDA approval changed the central question surrounding Travere. Before the decision, the market was focused on whether the agency would accept the totality of the FILSPARI evidence in FSGS after the Phase 3 DUPLEX trial produced a strong and durable proteinuria effect but did not meet the original eGFR slope endpoint in the full study population. The January review extension intensified that debate because the FDA classified Travere’s additional responses on clinical-benefit characterization as a major amendment and moved the action date to April. The company said the agency had not requested additional safety or manufacturing information, but the extension still reminded investors that clinical interpretation was not automatic.

Approval resolved the regulatory question for the population named in the label. FILSPARI is approved to reduce proteinuria in adults and children aged eight years and older with FSGS who do not have nephrotic syndrome. That wording is critical. The label creates a real commercial opportunity and gives Travere first-approved status in a serious rare kidney condition, but it is not an unrestricted FSGS label. Patient classification, medical records, proteinuria levels, albumin, edema and payer documentation can influence whether a particular patient fits the approved use and whether reimbursement proceeds smoothly.

The company estimated that the additional indication expands FILSPARI’s total U.S. addressable population across IgAN and FSGS to more than 100,000 patients, including more than 30,000 FSGS patients without nephrotic syndrome. Addressable population is not the same as treated population. It describes the theoretical field in which the company can work. Conversion to revenue requires diagnosis, specialist awareness, treatment selection, successful enrollment in support programs, prior authorization, pharmacy processing, patient acceptance, laboratory monitoring and persistence. The first full launch quarters are therefore more informative than the approval-day market reaction.

Q2 2026 is important because it begins that proof phase. FILSPARI revenue nearly doubled year over year and Travere reported 2,012 combined patient start forms across IgAN and FSGS. The number shows strong aggregate demand, but it does not provide a clean FSGS-only launch curve. Management’s decision not to break out PSFs by indication limits the precision of outside models. Investors can see that the franchise is growing; they cannot yet independently determine the exact portion attributable to new FSGS starts, continuing IgAN momentum or changes in timing between forms, reimbursement and recognized sales.

That disclosure limitation does not erase the positive quarter. It simply changes what can be claimed. The verified conclusion is that the total FILSPARI franchise strengthened materially during the quarter that included the April 13 FSGS approval. The unverified conclusion would be to assign all 2,012 forms to FSGS or to assume that every form becomes a reimbursed, persistent patient. Those categories stay separate.

05 FILSPARI Mechanism and Strategic Positioning

FILSPARI is a non-immunosuppressive, once-daily oral medicine that combines antagonism of the endothelin type A receptor and the angiotensin II type 1 receptor. The strategic concept is nephroprotection through dual pathway blockade. Endothelin and angiotensin signaling can contribute to glomerular injury, proteinuria, inflammation and progressive kidney damage. By addressing both pathways in one molecule, sparsentan aims to provide a differentiated reduction in proteinuria and a broader protective effect than conventional renin-angiotensin system blockade alone.

The mechanism creates a commercially useful narrative because nephrologists are familiar with angiotensin-pathway management and increasingly focused on reducing proteinuria as part of long-term kidney protection. It also creates complexity. FILSPARI is not simply another generic blood-pressure medicine. It has product-specific labeling, monitoring requirements, drug-interaction considerations and a REMS program. Physicians and patients must understand how it replaces rather than merely layers on top of certain background treatments. Commercial adoption therefore depends on both the strength of the evidence and the ease with which clinical teams can integrate the product into real-world workflows.

In IgAN, FILSPARI’s full FDA approval materially improved the durability of the commercial thesis. Accelerated approval based on proteinuria reduction had created uncertainty about confirmatory evidence and long-term status. Full approval established a stronger regulatory foundation and allowed Travere to present FILSPARI as a therapy intended to slow kidney-function decline in adults with primary IgAN at risk of progression. That indication remains the commercial anchor even after the FSGS expansion.

In FSGS, the mechanism is attractive because proteinuria is central to disease burden and progression. However, FSGS is heterogeneous. Primary, genetic, adaptive and immune-mediated forms may not behave identically, and the approved population excludes nephrotic syndrome. The commercial team therefore needs a sophisticated message that respects the label while helping physicians identify appropriate patients. A simplistic “all FSGS” narrative would be clinically and financially misleading.

The April 2026 FDA label retains boxed warnings for hepatotoxicity and embryo-fetal toxicity. FILSPARI is distributed through a REMS with enrollment requirements. The label requires liver testing before treatment and every three months during treatment, and contraindicates pregnancy and coadministration with ARBs, ERAs or aliskiren. The commercial implication is an ongoing monitoring and access workflow; full approval does not remove these obligations. FDA prescribing information

06 IgA Nephropathy: The Commercial Foundation

IgA nephropathy transformed Travere from a development company into a meaningful commercial business. FILSPARI received accelerated U.S. approval in February 2023 and full approval in September 2024. The launch required Travere to build or expand a nephrology-focused field organization, payer and reimbursement expertise, specialty-pharmacy processes, patient support and REMS operations. Those investments raised SG&A spending, but they also created infrastructure that can now support the FSGS indication.

The commercial progression before Q2 2026 was already strong. Full-year 2025 FILSPARI U.S. net product sales reached $322 million. Fourth-quarter 2025 sales were approximately $103 million with 908 new patient start forms. Q1 2026 then produced $105.2 million of FILSPARI sales and 993 new IgAN PSFs. The Q2 increase to $141.1 million indicates that demand accelerated further rather than flattening immediately after the first major growth period.

IgAN remains strategically important for three reasons. First, it supplies the recurring revenue base that funds the rest of the business. Second, it gives Travere prescriber relationships that can be used when educating nephrologists about FSGS. Third, it provides evidence that FILSPARI can achieve repeat adoption beyond an initial wave of specialists. A durable rare-disease franchise needs new prescribers, repeat prescribers and continued patient persistence; it cannot rely forever on a small group of early adopters.

The competitive environment is becoming more complex. IgAN is an active development and commercialization field, with therapies targeting immune drivers, complement pathways, B-cell biology and supportive nephroprotection. FILSPARI does not need every competing drug to fail in order to remain successful. Treatment may evolve toward sequencing and combination approaches. The relevant questions are where FILSPARI is positioned, which patients are considered appropriate, whether combination use expands and how payer policies respond as more branded options enter the market.

That means quarterly sales should not be read in isolation. What the quarterly line depends on is new PSFs, repeat-prescriber behavior, reimbursement timing, gross-to-net adjustments, discontinuation trends, inventory effects and conference data on real-world use. Strong reported sales can be supported by healthy patient growth, but they can also be influenced by timing and channel factors. Travere’s long-term valuation depends on the quality and persistence of the growth, not only one quarter’s percentage increase.

07 FSGS: Evidence, Label Nuance and the Real Launch Test

Focal segmental glomerulosclerosis describes a pattern of scarring in the kidney’s filtering units and can arise through different biological pathways. It is associated with proteinuria, progressive loss of kidney function and a risk of kidney failure. The absence of a previously FDA-approved medicine specifically for FSGS created significant unmet need, but it also meant that the regulatory and commercial path had fewer established precedents.

The Phase 3 DUPLEX program is central to understanding both the opportunity and the residual risk. The study compared sparsentan with irbesartan and showed a significant and sustained proteinuria effect. The original eGFR slope endpoint at the final analysis was not met in the full population. That result created a difficult regulatory package: the program had clear biological and clinical activity, but the pre-specified long-term kidney-function endpoint did not deliver a straightforward statistical victory.

The FDA’s eventual approval indicates that the agency found the totality of evidence sufficient for the labeled population. It does not retroactively turn the missed endpoint into a met endpoint, and it does not eliminate questions about how physicians interpret the data. Travere must communicate the approved use accurately, support education around patient selection and continue generating evidence, including open-label extension and real-world information.

The label’s exclusion of nephrotic syndrome deserves special attention. It narrows the field and may require careful documentation. In practice, payers may ask for evidence that a patient meets the approved criteria, and specialists may differ in how quickly they adopt FILSPARI across FSGS subtypes. This can make the launch slower and more uneven than a headline addressable-population estimate implies.

At the same time, Travere has several advantages. FILSPARI is already known to nephrologists. The company already operates patient services and REMS workflows. It entered the FSGS launch with commercial revenue rather than depending on external financing to build an organization from zero. The first patient start forms arrived immediately after approval and reimbursed treatment began within the first week, demonstrating operational readiness.

The most important unanswered question is the slope of the launch. Because Travere reported 2,012 combined IgAN and FSGS PSFs in Q2 without a separate indication breakdown, investors cannot yet determine the FSGS contribution with precision. The next several quarters should reveal whether the new indication broadens the prescriber base, produces incremental patient growth and supports operating leverage without requiring disproportionate spending.

08 Detailed Q2 Operating Bridge

Operating income of approximately $4.0 million marked a significant improvement from the operating loss reported a year earlier. This suggests that revenue growth began to overcome the company’s cost base during the quarter. It does not establish permanent profitability. Expenses can vary with launch activity, clinical enrollment, manufacturing, stock compensation, milestones and business-development spending. Still, positive operating income is a meaningful signal because it shows that the commercial model can potentially generate leverage.

The GAAP net loss of $34.8 million tells a different story because other expenses were dominated by the induced-conversion charge associated with the 2029 notes. The charge was economically linked to the decision to refinance and repurchase debt rather than to a collapse in product demand. This is why an EPS-only reading is inadequate. The GAAP loss is real and affects reported results, but it does not describe the same operating weakness that a large loss from the core business would have implied.

Non-GAAP adjusted results also require discipline. The company excludes stock compensation, amortization and specified tax items; its $8.979 million adjusted loss still includes the $40.008 million inducement charge. It is not a result excluding the refinancing expense, and it should not replace GAAP analysis. A balanced reading is that Q2 showed strong commercial growth and positive operating income, while the company still incurred material adjusted expenses and remained exposed to financing and share-count complexity.

The first-half comparison is also important. Q1 2026 included $127.2 million of revenue and a $37.1 million GAAP net loss. Q2 revenue rose sharply, but the GAAP loss remained because the financing charge replaced operating weakness as the main driver. The sequence suggests improving product economics, though investors need additional quarters to determine whether positive operating income persists after launch investment, royalties and pipeline expansion.

09 Revenue Quality, Gross-to-Net and Royalty Economics

Headline product sales are only the first layer of commercial analysis. Net product sales already reflect estimates for rebates, discounts, returns, patient assistance and other gross-to-net deductions. Changes in payer mix, channel inventory, Medicaid exposure, commercial insurance and patient-support programs can influence the relationship between patient demand and recognized revenue. Travere does not provide every component needed for a precise outside gross-to-net model each quarter, so analysts must avoid treating patient start forms and revenue as a fixed one-to-one conversion.

Royalty expense requires an accounting bridge rather than a fixed percentage extrapolation. Q2 royalty expense was $7.061 million versus $13.635 million a year earlier, a decline explained primarily by the Thiola intangible reaching the end of its useful life on March 31, 2026. First-half expense instead increased to $31.877 million from $26.060 million, including elevated Thiola amortization in Q1. FILSPARI royalties of 15–17% are capitalized and amortized: additions were $25.4 million in Q2 and $43.4 million in H1. The cash-flow statement separately places $43.249 million of intangible purchases in investing. Thus positive H1 operating cash flow of $17.705 million is not cash generation after those purchases, and lower royalty expense does not demonstrate lower royalty cash costs. Primary source

Milestone and collaboration revenue can make total revenue volatile. A quarter may contain payments from regional partners linked to regulatory, market-access or sales achievements. These payments can strengthen cash generation without indicating the same recurring commercial trend as product sales. For valuation, FILSPARI net sales are the recurring core; milestones are useful but episodic.

The cleanest quarterly scorecard therefore separates: U.S. FILSPARI sales, tiopronin sales, collaboration revenue, royalty expense, commercial spending, R&D spending and financing items. Combining everything into a single revenue or EPS headline can hide the actual direction of the business.

10 Convertible Notes, Dilution and Capital Allocation

The May 2026 refinancing materially changed Travere’s capital structure. The company issued $525 million aggregate principal amount of 0.50% convertible senior notes due 2032. It used part of the proceeds to repurchase approximately $221 million principal amount of the 2029 convertible notes and reported approximately $158 million of net proceeds from the related transactions. The strategy extended the maturity profile and increased liquidity, but it did not create free capital.

Convertible notes combine debt and potential equity exposure. Until conversion conditions are met, they create interest and repayment obligations. If conversion becomes economically attractive or contractually available, they can lead to share issuance or other settlement effects. The exact future dilution depends on note terms, stock price, conversion mechanics, capped-call or related arrangements, company settlement choices and future amendments. It is therefore incorrect to assume either zero dilution or immediate full dilution.

The repurchase of a large portion of the 2029 notes reduced a nearer-term overhang, but the induced-conversion expense created the main Q2 GAAP earnings distortion. The transaction can be strategically rational even though it produced a large accounting charge. What it is judged by is the resulting maturity profile, net cash retained, remaining 2029 principal, 2032 conversion exposure and the company’s use of the additional liquidity.

Capital allocation became more important when Travere agreed to pay Everest $112.5 million upfront for civorebrutinib. The agreement may expand the future pipeline, but the cash outflow occurred shortly after the debt financing. This sequence should be read as a deliberate choice to use a stronger balance sheet to buy pipeline optionality. Success would reduce long-term dependence on FILSPARI. Failure would mean that debt-supported liquidity helped fund an asset that did not create sufficient value.

Common-share dilution must also be tracked separately from convertibles. Shares outstanding increased from approximately 90.92 million at year-end 2025 to approximately 94.17 million at June 30, 2026. Equity compensation, employee grants and other issuance can gradually reduce each existing holder’s percentage ownership even without a marketed stock offering. Both reported shares outstanding matter and the potential dilution embedded in convertibles and incentive plans.

The cash-flow statement makes the refinancing arithmetic explicit: $525.000 million issued less $16.270 million issuance costs and $350.885 million repurchase payments equals $157.845 million. The last line includes the repurchase premium; it is much larger than the $221.4 million face amount retired. Other financing activity takes total first-half financing inflow to $191.721 million. This separates retained cash, debt principal and accounting expense. Primary source

The remaining 2029 principal is about $94.9 million with a 2.25% coupon and March 1, 2029 maturity; the $525 million 2032 tranche carries 0.50% and matures May 15, 2032. Initial conversion prices are approximately $31.87 and $64.90 respectively. Conversion is governed by the indentures, and settlement may use cash, shares or both at the company’s election; these prices are not automatic dilution triggers. The June balance-sheet carrying amount of $602.781 million differs from face principal because of unamortized issuance costs.

11 Civorebrutinib: Strategic Logic and Development Risk

Civorebrutinib, also known as EVER001, is an investigational oral covalent-reversible Bruton’s tyrosine kinase inhibitor. BTK is involved in B-cell receptor signaling and the activation, survival and differentiation of B lymphocytes. In antibody-mediated and other immune-driven kidney diseases, reducing pathological B-cell activity may affect autoantibody production and downstream glomerular injury.

The Everest agreement gives Travere rights outside China and specified East and Southeast Asian territories. Everest is eligible for the $112.5 million upfront payment, up to approximately $1.03 billion in additional clinical, regulatory and commercial milestones across as many as five indications, and tiered royalties ranging from high-single-digit to double-digit percentages depending on annual sales thresholds.

Management has described civorebrutinib as a potential pipeline-in-a-product. The initial strategic areas include primary membranous nephropathy, immune-mediated FSGS and minimal change disease, with possible expansion into additional immune-mediated rare kidney disorders. This is attractive because Travere already has nephrology relationships and a commercial identity in rare kidney disease. If the mechanism proves effective across several conditions, the company could use one asset to deepen the same specialist franchise.

The risk is that “pipeline-in-a-product” language can encourage investors to value multiple indications before the necessary trials exist. Early proof-of-concept observations are not equivalent to pivotal evidence. Travere still needs to define dose, target populations, endpoints, duration, comparator strategy, safety monitoring, development sequence and regulatory interactions. BTK inhibitors also have a broader class history that makes selectivity, reversibility, off-target activity and long-term tolerability important.

The deal should therefore be valued as structured optionality rather than approved-product economics. The best near-term signals will be a disciplined development plan, clear prioritization of the first indication, evidence that Travere is not duplicating costs inefficiently and confirmation that the company can fund the program without undermining FILSPARI execution or HARMONY.

12 Pegtibatinase and Classical Homocystinuria

Pegtibatinase, formerly TVT-058, is a PEGylated recombinant enzyme replacement therapy being developed for classical homocystinuria. Classical HCU is a rare inherited metabolic disorder associated with markedly elevated total homocysteine and serious risks that can include thrombotic events, eye complications, skeletal abnormalities and developmental effects. Existing management may include dietary restriction, vitamin B6 and betaine, but many patients remain inadequately controlled.

The Phase 3 HARMONY study plans approximately 70 patients aged 12–65 on standard care. General eligibility requires total homocysteine of at least 80 micromoles per liter; up to 18 patients may have levels from 50 to below 80. The registry, updated October 2, lists estimated primary completion in August 2027. Trial registry Participants are randomized to pegtibatinase or placebo for a blinded period. The primary endpoint evaluates change from baseline in plasma total homocysteine averaged across weeks 6 through 12, with durability through week 24 serving as an important secondary measure.

The program carries Breakthrough Therapy, Fast Track, Rare Pediatric Disease and orphan-related designations. These designations can support interaction and development efficiency, but they do not replace the need for a successful trial or reliable manufacturing. The manufacturing-scale-up issue that caused Travere to pause enrollment in 2024 remains part of the risk history. The company later optimized the process, restarted enrollment and dosed the first new patient in April 2026.

Topline HARMONY data remain expected in the second half of 2027. That timeline makes pegtibatinase strategically important but not a near-term earnings driver. A positive result could establish a second rare-disease franchise outside kidney disease and reduce concentration around FILSPARI. A delay, manufacturing recurrence or clinical disappointment would leave Travere more dependent on sparsentan and make the civorebrutinib development plan more important.

13 Management, Leadership Transition and Governance

September 23 update: the September 21 announcement adds a separate CEO succession to the R&D transition discussed below. Bradley L. Campbell becomes president, CEO and board member on December 1, 2026. Eric Dube serves until then and remains executive advisor through February 15, 2027. Company announcement.

Eric Dube’s commercial and operational background fits the company’s current stage, but Travere is also preparing for an important R&D leadership transition. In June 2026, the company announced that Chief Research Officer William Rote, Ph.D., plans to retire in February 2027 after approximately a decade of service. Jula Inrig, M.D., currently chief medical officer, is expected to expand her role and become executive vice president, head of research and development and chief medical officer.

Dr. Inrig is a nephrologist with experience in clinical development, trial execution and global regulatory strategy. Continuity matters because Travere must manage HARMONY, define the civorebrutinib program, support FILSPARI evidence generation and maintain regulator relationships at the same time.

Governance should be evaluated through outcomes rather than titles. What can be followed is whether management maintains clear disclosure around PSFs, launch trends, debt transactions and pipeline timelines. Compensation and equity plans matter because a company can produce strong product growth while still diluting shareholders through stock awards. Planned leadership succession, board oversight and capital-allocation decisions are therefore part of the investment thesis, not administrative details.

What management delivered was moving FILSPARI from accelerated to full approval in IgAN, securing the FSGS approval after a difficult review, restarting HARMONY and improving commercial scale. The critical test now is whether the organization avoids overextension. The company is simultaneously launching a second indication, funding a Phase 3 metabolic program, integrating a new licensed asset, managing regional partnerships and servicing a more complex balance sheet.

14 Competitive Landscape and Read-Through

Travere operates in a rapidly changing kidney-disease market. IgAN has attracted therapies that target different parts of disease biology, including immune modulation, B-cell pathways, complement and targeted supportive approaches. This creates competition for prescriber attention, payer budgets and treatment sequencing, but it can also expand diagnosis and specialist awareness across the category.

FILSPARI’s differentiation rests on oral administration, dual endothelin and angiotensin receptor activity, non-immunosuppressive positioning and an established commercial presence. Competing immune-directed products may be used in different patients or at different stages. The future market may not produce one universal winner. Instead, nephrologists may combine or sequence therapies based on proteinuria, kidney function, immunological activity, risk tolerance, comorbidities and payer access.

In FSGS, first-approved status provides an advantage because Travere can shape education and real-world experience before another specifically approved product reaches the market. The advantage is not permanent. Development activity is likely to continue, especially after regulatory validation of the commercial opportunity. Future competitors may target immune forms, genetic pathways, podocyte biology or other mechanisms.

Vera Therapeutics and other IgAN-focused companies provide relevant read-through because successful launches or clinical data can change expectations for how nephrologists sequence disease-modifying therapies. Larger rare-disease companies provide a different comparison: they show that specialist infrastructure and high-value products can create durable franchises, but also that payer scrutiny and concentrated pipelines can limit valuation.

Ligand remains an economic read-through because of its sparsentan-related royalty interests. Regional partners such as CSL Vifor and Chugai matter because international approvals, market access and sales can generate milestones and royalties for Travere without requiring the company to build a full global commercial organization. Partner progress belongs to the same picture even when U.S. sales remain the main valuation driver.

15 International Strategy, Partnerships and Intellectual Property

Travere’s international strategy relies heavily on partners. CSL Vifor holds rights in Europe and other territories, while Chugai is developing sparsentan in Japan. This model allows Travere to participate in international value through milestones and royalties without bearing every commercial cost directly. It also means that timing and execution are partly outside Travere’s control.

Chugai submitted a Japanese New Drug Application for sparsentan in June 2026. A successful review could create regulatory milestones and a future royalty stream. The exact timing, label and commercial contribution remain uncertain until the Japanese regulatory process advances.

Intellectual property matters because FILSPARI is becoming a larger franchise. In May 2026, Travere announced a notice of allowance for a U.S. patent application directed to certain methods of using FILSPARI in IgAN, with expected method-of-use coverage extending into 2037 upon issuance, subject to the final patent and normal legal limitations. According to the company, that IgAN patent was granted in August 2026. On September 23, 2026 Travere announced a second notice of allowance, for Application No. 19/253,120 directed to certain methods of using FILSPARI in FSGS, with expected coverage into October 2037 once the patent issues and a planned Orange Book listing after grant. Method-of-use patents can strengthen protection, but they are not identical to composition-of-matter patents and may be challenged or designed around.

What is worth following is the Orange Book, patent issuance, litigation, generic filings and exclusivity periods rather than relying on one headline date. The durability of FILSPARI economics depends on a portfolio of regulatory exclusivity, patents, know-how, REMS and commercial execution.

16 Quarterly Earnings Checklist

17 Catalyst and Execution Timeline

April 13, 2026 — FILSPARI FSGS approval. Adults and children aged eight and older with FSGS without nephrotic syndrome.

May 2026 — Convertible financing. $525 million of 2032 notes issued; approximately $221 million of 2029 principal repurchased.

June 2026 — Japan NDA. Chugai submitted sparsentan for review.

July 2026 — Civorebrutinib deal. $112.5 million upfront paid to Everest.

August 4, 2026 — Q2 results. $169.6 million revenue, $141.1 million FILSPARI sales and 2,012 combined patient start forms.

October 21–25, 2026 — ASN Kidney Week. Nine presentations announced, including the October 22 SPARTAN poster; headline SPARTAN and post hoc DUPLEX findings were released October 2.

December 1, 2026 — CEO transition. Bradley Campbell succeeds Eric Dube; the advisory period ends February 15, 2027.

Second half 2026 — SPARLIGHT window. Study initiation expected; no fixed day announced.

2027 — SPARX window. Data expected in post-transplant recurrent IgAN and FSGS.

Second half 2027 — HARMONY window. Company guidance for Phase 3 pegtibatinase topline data, distinct from the registry completion estimate.

ASN announcement · CEO filing

18 What to Watch Next

The next earnings report carries five specific measures: FILSPARI sales growth, any improvement in indication-level FSGS disclosure, combined PSF momentum, operating income before financing items and the cash balance after the Everest payment. Also worth following are royalty expense, gross-to-net commentary, share count and any additional transactions involving the remaining 2029 notes.

For the pipeline, the next useful information will be the SPARLIGHT design, civorebrutinib development sequence, HARMONY enrollment progress and confirmation that the second-half 2027 readout remains intact.